contract deal...will set it 40c, page-4

“The ability to control the delivery of a drug to a targeted depth is a significant development. The ability to deliver a
drug to a designated depth can both increase the efficacy of a drug, as well as possibly enable a decrease in the
amount of ‘drug’ needed to achieve the required therapeutic or prophylactic outcome.
While the technology was primarily developed as part of the ‘Needle-free Injection’ project, the patent may have
wider applications.”

And from a previous announcement

“Finally, commercial negotiations are at an advanced stage in respect of the further development, deployment and distribution of the KarmelSonix product range, including the WIM-PC and other products currently under development. A further announcement in respect of these negotiations is expected in the near term.”